Isomorphic Labs, an artificial intelligence-driven drug discovery company, said on Wednesday it has raised $2.1 billion in its ​latest funding round led by existing investor Thrive Capital. The ‌funding round, completed at an undisclosed valuation, also included other existing investors, Google Ventures and Alphabet, along with new backers MGX, Temasek and CapitalG. The ​development comes amid a broader industry push to demonstrate ​practical applications of AI in the healthcare sector, including ⁠its ability to accelerate research and development along with shortening ​drug discovery timelines. “This capital injection allows us to build out our ​drug design engine at scale, driving us forward in our mission to solve all diseases,” said founder and CEO Demis Hassabis. Isomorphic was founded in 2021 ​as a spin-off from Google DeepMind, an AI research lab ​acquired by Alphabet in 2014.

Full report : Isomorphic Labs, an AI-powered drug discovery spinoff from Google DeepMind, raised $2.1 billion led by Thrive, after raising $600 million in its first round in March 2025.